A 25-year veteran of the biotechnology and life sciences industry, Mark W. Schwartz, PhD, has extensive experience in strategic planning, business development, and clinical and product development. A faculty member of San Jose State University since 2010, he serves as a board member for the school’s biotechnology program and teaches an entrepreneurship class focused on the funding and operation of a biotechnology start-up. Mark W. Schwartz concurrently serves as a director of the San Diego-based biopharmaceutical company Targazyme, Inc.
Previously, Dr. Schwartz was the president and CEO of Bayhill Therapeutics, Inc., in which role he raised more than $100 million in equity and nondilutive funding for a gene treatment of autoimmune diseases. He has also held key leadership positions with firms such as Calyx Therapeutics, Inc., and Trega BioSciences, Inc. Mark W. Schwartz holds a bachelor of arts in chemistry from Grinnell College, where he worked as a chemistry tutor and was captain of the soccer team. He later earned a PhD in chemistry and biochemistry from Arizona State University. He has served on the boards of the Biotechnology Industry Association and its Emerging Companies Section Governing Board.
Discovery Bay, CA , US
Mark W. Schwartz concurrently serves as a director of the San Diego-based biopharmaceutical company Targazyme, Inc.
A faculty member of San Jose State University since 2010, he serves as a board member for the school’s biotechnology program and teaches an entrepreneurship class focused on the funding and operation of a biotechnology start-up.
Mark W Schwartz later earned a PhD in chemistry and biochemistry from Arizona State University. He has served on the boards of the Biotechnology Industry Association and its Emerging Companies Section Governing Board.
Mark W. Schwartz holds a bachelor of arts in chemistry from Grinnell College, where he worked as a chemistry tutor and was captain of the soccer team.